Canopy Growth Corporation, trading on the NASDAQ under the symbol CGC, is a prominent player in the cannabis industry. The company is involved in the production and sale of cannabis and cannabis-related products. It faces competition from other major cannabis companies like Aurora Cannabis and Tilray. Recently, Alliance Global Partners maintained a Neutral rating for CGC, advising investors to hold their positions.
On February 6, 2026, Alliance Global Partners adjusted their price target for CGC from C$2.50 to C$1.80, as highlighted by TheFly. At the time, CGC's stock price was $1.10. This adjustment reflects a cautious outlook, despite the company's recent fiscal third-quarter results showing some positive trends.
Canopy Growth's net revenue for the quarter was C$74.5 million, exceeding the Wall Street consensus estimate of C$70.5 million. However, the company reported a loss of C$0.18 per share, which was higher than the expected C$0.08 loss per share. This indicates challenges in achieving profitability, although the loss per share improved by approximately 84% from the previous year.
The company's net loss narrowed by 49% year over year, and the adjusted EBITDA loss decreased by 17%. This improvement is attributed to stronger sales execution and reduced selling, general, and administrative (SG&A) expenses. Canopy Growth's cannabis net revenue increased by 4% to C$52 million, with Canadian medical cannabis revenue rising by 15% to C$23 million.
CGC's stock is currently priced at $1.10, reflecting a 1.85% increase with a change of $0.02. The stock has fluctuated between $1.08 and $1.14 today, with a 52-week high of $2.38 and a low of $0.77. The company's market capitalization is approximately $566 million, and today's trading volume on the NASDAQ is 11,032,019 shares.
